Explore tweets tagged as #CM274
Fantastic discussant session from @ERPlimackMD this morning at #GU25. 🔍 Role of peri-op IO in MIBC: #CM274 & #NIAGRA. 🧬 Biomarker need to optimise stratification and minimise risk of over-treatment. ➡️ Emerging risk adapted integrated biomarker driven studies (MODERN)
0
1
4
Excellent discussion by @ERPlimackMD on #CM274 which continues to show OS benefit with caveats:.➡️how can we avoid over treatment -> use of biomarkers - ctDNA, PDL1?.➡️only 50% got SOC NAC.➡️pts wouldn’t have received EV/P upon progression .➡️use of subQ nivo in future?.#GU25
1
20
43
🗣️Bladder Cancer Oral Abstracts #GU25. Dr @ERPlimackMD discussing Abs658 & Abs659: #CM274 #NIAGARA. #CM274 Can ctDNA and PDL1 improve patient selection? #MODERN. #NIAGARA Can we ascertain contribution of component parts for NeoAdj vs Adjuvant PD1 therapy? . 👥 @DrRosenbergMSK
1
7
15
🗣️Bladder Cancer Oral Abstracts #GU25. Dr @MattMilowsky presenting Abs658 Adjuvant NIVO for MIBC: efficacy and OS #CM274. N = 709 .560 (79%) MIBC (NIVO = 279; PBO = 281); .284 (51%) MIBC w/ prior NAC.Median FU 36.1mo. ♦️NIVO.♦️PLACEBO. ITT.✅ DFS: NIVO 25.6mo vs P 8.5mo (0.63;
1
9
20
. ⬇️💡 Subsequent Tx are key. #CM274 OS data is very exciting for EU countries where EV is 🚫 and (likely) will take some ⏱️ to get it. Although ~ pts will be overtreated and SDM will be needed. Conversely, I don't think there will be much enthusiasm in the US b/c EVP ✅ (?).
Great questions @niklas_kluemper Ambassador was only in US vs CM274 was broader:access to subsequent Tx may differ. Cross-over to IO before or after recurrence may impact OS & explain Ambassador. EV/P data so impressive but with palliative intent (adjuvant Tx has curative intent).
0
0
0
Updates on #CM274 by @MattGalsky adjuvant nivo vs pcb x1yr in MIBC & commentary by Dr. Heijden #GU23:.🌀DFS 22.0mo vs 10.9mo (HR 0.71).🌀PDL1+: 52.6mo vs 8.4mo (HR 0.52).🌀Subgroup w no NAC, no benefit.🌀Primarily white men ECOG 0-1.🌀Await OS data.🌀Other adjuvant IO trials (-)
0
7
19
#GU23 Phenomenal discussion of #KN057 and #CM274 to conclude Oral Abstract Session B.Awaiting OS results from #CM274 . @NKI_nl #VanDerHeijden.@OncoAlert
0
9
14
Ahead of the HOT discussion b/w @tompowles1 @MattGalsky tomorrow on adjuvant IO #CM274 and IMVigor010in MIUC #BladderCancer session #UromigosLive @Uromigos, we NEED your votes to this poll please! 👇👇👇🙏🙏. @apolo_andrea 🕊. @brian_rini @montypal @neerajaiims @DrRosenbergMSK.
The #UromigosLive Poll Q1: @US_FDA approved adjuvant Nivo for all high risk UC pts but @EMA_News approved Nivo only for pts with PD-L1 + tumors. In IMVigor010 trial, ctDNA +pts had improved DFS&OS with atezo. Based on this info, in MIBC, adjuvant Nivo should be used in.
0
1
4
Great GU debate by @MattGalsky & @shilpaonc:.❓adjuvant Nivolumab in pT3N1 UC w extensive squamous features, cisplatin ineligible (no NAC).❗️These patients were excluded from #CM274 but molecular subtype may suggest response to IO. Perhaps #AMBASSADOR will help answer this.
1
3
24
Great discussion w @IyerGopa #ArleneSiefkerRadtkeMD #SethLernerMD re: #biomarkers & #bladdercancer. Broad support for #PROOF302 - even in face of exciting data from #CM274, so critical to keep this & the "tie-breaker" @ALLIANCE_org #AMBASSADOR in mind!
0
7
12
Hoping you will join us tonight from 5:30-7pm PT to discuss the latest & greatest from @ASCO #GU21 w @TiansterZhang @PGrivasMDPhD & @YungLyou - should be a lot of fun! We will cover #CLEAR, #9ER, .@SWOG 1500, #EV301, #CM274 & more!
Excited to share the results of @SWOG 1500, which we are presenting at @ASCO #GU21 & reporting in @TheLancet today. 1st, THANK YOU to patients & families. 2nd, hats off to a tremendous group of investigators. This was a team effort! Wanted to share how it all began: (1/13)
0
4
18
Excellent summary @montypal DFS benefit promising #CM274 congrats @MattGalsky Dr. Bajorin. Await #ambassador results @apolo_andrea .#PROOF-302 for FGFR altered UTUC/B ca led by you and @siadaneshmandwill help understand role of FGFRi in this space
My take on #CheckMate274: Is adj CPI now SOC for #MIUC? Not yet. Here's the design presented today at @ASCO #GU21 - first, thanks to patients & investigators (#DrDeanBajorin, @MattGalsky) who should be commended for completing an adj trial in #bladdercancer - no small feat! (1/9)
0
3
4
reflecting on Day 2 data, I read this amazing tweetorial by @montypal with clear thinking & awesome delivery! #CM274 is a landmark adjuvant trial, kudos to @MattGalsky Bajorin et al. great job! Impressive DFS, esp. for PDL1+; OS is event-driven & is needed IMO to change practice.
My take on #CheckMate274: Is adj CPI now SOC for #MIUC? Not yet. Here's the design presented today at @ASCO #GU21 - first, thanks to patients & investigators (#DrDeanBajorin, @MattGalsky) who should be commended for completing an adj trial in #bladdercancer - no small feat! (1/9)
0
3
10
0
0
0
